Getting to an ImprOved Understanding of Low-Density Lipoprotein-Cholesterol and Dyslipidemia Management (GOULD): Methods and baseline data of a registry of high cardiovascular risk patients in the United States

Cannon, Christopher P.; Lemos, James A. de; Rosenson, Robert S.; Ballantyne, Christie M.; Liu, Yuyin; Yazdi, Daniel; Elliott‐Davey, Mary; Mues, Katherine E.; Bhatt, Deepak L.; Kosiborod, Mikhail; Investigators, Gould

doi:10.1016/j.ahj.2019.10.014

Cited by 19 publications

(18 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…More men than women were prescribed statins before stroke and a putative explanation for this may be the reported higher frequency of ischemic heart disease in men, 41 although not explored in the present study. After hospital care, women were still less likely than men to be prescribed statins.…”

Section: In-hospital Stroke Managementmentioning

confidence: 60%

Sex differences in risk factors, treatment, and prognosis in acute stroke

Dahl

Hjalmarsson

Andersson

2020

Womens Health (Lond Engl)

View full text Add to dashboard Cite

Objectives: Stroke is a major cause of long-term disability and death worldwide. Several studies have shown that women in general have more severe symptoms at arrival to hospital and are less likely to return home and independent living. Our aim with the present study was to update previous results concerning sex differences in baseline characteristics, stroke management, and outcome in a population study from Sahlgrenska University Hospital, Gothenburg, Sweden. Methods: This study included patients with acute ischemic and hemorrhagic stroke in 2014 at Sahlgrenska University Hospital. All data were collected from The Swedish National Stroke Registry (Riksstroke). Results: The study population consisted of 1453 patients, with 46.7% females. Women were 5 years older than men. There was no sex difference in acute stroke severity. Frequency of revascularization was equal between men and women. The stroke mortality rate was the same between the sexes. At 3-months follow-up, women had a worse functional outcome and a higher frequency of depression and post-stroke fatigue. Conclusion: Our results show that there are no sex differences in management of acute stroke. However, the cause of worse functional outcome in women at 3-months follow-up, independent of other risk factors, is not clear and warrants further investigations.

show abstract

Section: In-hospital Stroke Managementmentioning

confidence: 60%

Sex differences in risk factors, treatment, and prognosis in acute stroke

Dahl

Hjalmarsson

Andersson

2020

Womens Health (Lond Engl)

View full text Add to dashboard Cite

show abstract

“…Furthermore, peripheral cells also express the LDL receptor, apoB-100. As LDL-targeted cells include cells of the vascular endothelium, high concentration and activity of LDL have serious implications in the etiology of CVDs [48]. LDL contributes to the formation of plaque, which is a thick, hard deposit that can clog the arteries, thereby compromising the flexibility of arteries, resulting in atherosclerosis [49].…”

Section: Ldl-cmentioning

confidence: 99%

Menopause-Associated Lipid Metabolic Disorders and Foods Beneficial for Postmenopausal Women

2020

View full text Add to dashboard Cite

Menopause is clinically diagnosed as a condition when a woman has not menstruated for one year. During the menopausal transition period, there is an emergence of various lipid metabolic disorders due to hormonal changes, such as decreased levels of estrogens and increased levels of circulating androgens; these may lead to the development of metabolic syndromes including cardiovascular diseases and type 2 diabetes. Dysregulation of lipid metabolism affects the body fat mass, fat-free mass, fatty acid metabolism, and various aspects of energy metabolism, such as basal metabolic ratio, adiposity, and obesity. Moreover, menopause is also associated with alterations in the levels of various lipids circulating in the blood, such as lipoproteins, apolipoproteins, low-density lipoproteins (LDLs), high-density lipoproteins (HDL) and triacylglycerol (TG). Alterations in lipid metabolism and excessive adipose tissue play a key role in the synthesis of excess fatty acids, adipocytokines, proinflammatory cytokines, and reactive oxygen species, which cause lipid peroxidation and result in the development of insulin resistance, abdominal adiposity, and dyslipidemia. This review discusses dietary recommendations and beneficial compounds, such as vitamin D, omega-3 fatty acids, antioxidants, phytochemicals—and their food sources—to aid the management of abnormal lipid metabolism in postmenopausal women.

show abstract

“…However, many patients cannot take statins and fewer than half of eligible patients receive recommended high-intensity statin therapy. [2][3][4][5] Therefore, combination therapies, with and without, statin therapy need to be investigated.…”

Section: Introductionmentioning

confidence: 99%

Lipid lowering with bempedoic acid added to a proprotein convertase subtilisin/kexin type 9 inhibitor therapy: A randomized, controlled trial

Rubino

MacDougall

Sterling³

et al. 2021

Journal of Clinical Lipidology

View full text Add to dashboard Cite

Background: Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9is) lower low-density lipoprotein cholesterol (LDL-C) in patients with hypercholesterolemia. However, some patients receiving PCSK9i therapy might require additional lipid-lowering therapy (LLT) to reach LDL-C goals. Bempedoic acid is an oral, once-daily, ATP-citrate lyase inhibitor that significantly lowers LDL-C in patients with hypercholesterolemia when given alone or as add-on therapy to statins and/or ezetimibe.Objective: Assess safety and efficacy of bempedoic acid added to PCSK9i (evolocumab) background therapy in patients with hypercholesterolemia.Methods: This phase 2, randomized, double-blind, placebo-controlled study was conducted in three phases: 1.5-month screening/washout period including discontinuation of all LLTs, a 3-month period wherein patients initiated background PCSK9i therapy; and a 2-month treatment period in which patients were randomized 1:1 to receive bempedoic acid 180 mg or placebo once daily while continuing PCSK9i therapy.Results: Of 59 patients randomized, 57 completed the study. Mean baseline LDL-C after 3 months of PCSK9i background therapy was 103. 1 ± 30.4 mg/dL. Bempedoic acid added to background PCSK9i therapy significantly lowered LDL-C by 30.3% ( P < .001) vs placebo. Compared with placebo, bempedoic acid significantly lowered apolipoprotein B, non-high-density lipoprotein cholesterol, and total cholesterol (nominal P < .001 for all), and high-sensitivity C-reactive protein ( P = .029). When added to background PCSK9i therapy, the safety profile of bempedoic acid was comparable to that observed for placebo.Conclusions: When added to a background of PCSK9i therapy, bempedoic acid significantly lowered LDL-C levels with a safety profile comparable to placebo in patients with hypercholesterolemia.

show abstract

Getting to an ImprOved Understanding of Low-Density Lipoprotein-Cholesterol and Dyslipidemia Management (GOULD): Methods and baseline data of a registry of high cardiovascular risk patients in the United States

Cited by 19 publications

References 33 publications

Sex differences in risk factors, treatment, and prognosis in acute stroke

Sex differences in risk factors, treatment, and prognosis in acute stroke

Menopause-Associated Lipid Metabolic Disorders and Foods Beneficial for Postmenopausal Women

Lipid lowering with bempedoic acid added to a proprotein convertase subtilisin/kexin type 9 inhibitor therapy: A randomized, controlled trial

Contact Info

Product

Resources

About